Ginkgo Bioworks draws attention as healthcare strength meets caution around synthetic biology, platform growth, and execution ...

Ginkgo Bioworks announces a partnership to work with Novo Nordisk's medicines for serious chronic diseases, including diabetes and obesity. The company also announces the acquisition of AgBiome's ...

Find the latest Ginkgo Bioworks Holdings, Inc. (DNA) stock quote, history, news and other vital information to help you with your stock trading and investing.

The average one-year price target for Ginkgo Bioworks Holdings (NYSE:DNA) has been revised to $10.88 / share. This is a decrease of 11.11% from the prior estimate of $12.24 dated November 7, 2025. The ...

Ginkgo Bioworks Holdings, Inc. (DNA) could be a solid choice for investors given its recent upgrade to a Zacks Rank #1 (Strong Buy). This upgrade primarily reflects an upward trend in earnings ...

Ginkgo Bioworks Holdings, Inc. (DNA) shares rallied 18.9% in the last trading session to close at $11.25. This move can be attributable to notable volume with a higher number of shares being traded ...

Ginkgo Bioworks Holdings Inc (NYSE:DNA) shares continue to trade higher after rising nearly 10% on Tuesday. Here’s a look at what’s going on. What To Know: Ginkgo Bioworks shares appear to be getting ...

) has been revised to $10.88 / share. This is a decrease of 11.11% from the prior estimate of $12.24 dated November 7, 2025. The price target is an average of many targets provided by analysts. The ...